Sorry, but difficult to unterstand your post... To meet Nasdaq listing criteria it needs to trade above $1 min. 1 moment within a year. So args could get in trouble for that reason in spring! No matter what some "experts" on other boards say. It's an early stage biotech. They usually dilute to finance their research, high risk for investors. But it's calculable imo bc the very bottom around 0,17 held twice so far. At least another 20-30% gains possible from here
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.